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Gastric cancer is the second most common cancer 
and a leading cause of cancer-related death world-
wide associated with poor response to the chemo- 
and radiotherapy [1, 2]. Therefore new approaches 
to the treatment of patients with gastric cancer 
(GC) may be promising [3–5]. Among them there is 
immunothera py that is available for to-day: there are 
implemented the clinical use of immunomodulators, 
monoclonal antibodies and their conjugates as well 
anticancer vaccines which elicit specific antitumor 
immune response by means of tumor-associated an-
tigens (TAA) and adjuvants [6, 7]. For clinical setting 
vaccines must be safe, effective against the identical 
tumor histological types and have stable proper-
ties [8].
At the same time it is known that disease outcome 
of patients diagnosed as having both the same stage 
of disease and tumor histological type may vary 
to a degree and advance of disease depends on the 
level of expression of the number of definite tumor 
proteins [9]. In our recent studies [10, 11] it has been 
shown the prognostic significance of the expression 
of Bcl-2 family proteins, receptors with tyrosine kinase 
activity, adhesion molecules and vascular endothelial 
growth factor (VEGF) for the patients with GC using 
both the immunocyto- and immunohystochemistry. 
In particular it was revealed that expression of p53 and 
VEGF is observed in diffuse type of carcinoma 
in patients with advanced disease and having poor 
survival time as a rule. Contrary it was shown that 
Bcl-2 expression in tumor on the early stage of di-
sease is the marker of worse outcome. The expression 
in tumor both receptors of tyrosine kinase (EGFR and 
HER-2/neu) also testify the unfavorable prognosis for 
GC patients. The availability in tumor of E-cadherin 
is correlated with lymph node metastases free and 
observed on the early stages of disease. In tumor tis-
sue of patients who have not distant metastases the 
expression of β-catenin was determined, and VEGF 
expression was clearly associated with stomach wall 
lesions. It was proved that expression of E-cadherin 
and α-catenin are the main features of intestinal type 
of GC on the early stages of disease and associated 
with favorable prognosis for patients with GC.
It should be mentioned that at present there are a lot 
of clinical data as to efficacy of autovaccines (AV) ap-
plied to prevent recurrence and metastasis in patients 
with GC [3, 5, 12, 13] but at the same time relationship 
between the vaccinotherapy efficiency and tumor 
molecular profile remains still not clear. The aim of this 
study was to evaluate the significance of molecular 
factors having prognostic values for disease outcome 
in patients with GC under application of the AV with as-
sessment of its efficacy in clinical setting.
Patients. Tissue samples were taken from 
150 patients with primary GC who have been treated 
in the “National Cancer Institute” (Ministry of Health 
of Ukraine, Kiev) between 1998 and 2007. The study 
included 86 patients with GC underwent AV after 
ope ration (subtotal resection or gastrectomy, group 
A) and 64 patients underwent operation only (group 
B). None of patients did not undergo preoperative 
radio- or chemotherapy. Adjuvant chemotherapy was 
not applied because of the rejection of patients to be 
treated or there were no indications to use it. All pa-
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tients provided written consent to perform the study. 
Clinicopathological characteristics of patients with 
GC are presented in Table 1.
Table 1. Clinico-pathological characteristics of the GC patients
Indices Group A (n = 86) Group B (n = 64)
Gender Male 48 35
Female 38 29
TNM Stage II 14 15
III 34 20
IV 38 19
Gastric wall 
invasion (Т)
T1–2 5 7
T3 42 38
T4 39 19
Lymph node 
metastasis (N)
N0 37 26
N1 30 15
N2 19 23
Distant 
metastases (М)
М0 74 60
М1 12 4
Grade of differen-
tiation (G)
G1–2 18 15
G3 36 25
G4 32 24
Autovaccine preparation and administration. 
Tumor tissue speciments have been obtained during 
operation and were snap frozen and stored at –20 °C 
until use. AV were prepared from autologous tumor 
cells and products of Bacillus subtilis B-7025 [14]. 
It is corresponded to International and State standards 
and is permitted to clinical apply in Ukraine (Certificate 
of State registration of immunological drug № 411/03-
300200000, January 09, 2003).
The onset of vaccination was on the 10–14 day 
after operation provided as subcutaneous injec-
tions of 3 ml of AV (9.0–12.0 mg of proteins) and was 
performed triply with 7 day intervals. Revaccinations 
were repeated in one month and in six months at the 
same manner.
Immunohistochemical examination. Expression 
of p53, Bcl-2, EGFR, VEGF, HER-2/neu, E-cadherin, 
α- and β-catenin have been evaluated by means of im-
munohistochemical staining using specific monoclonal 
antibodies [15]: for p53, Bcl-2 — clones DO-7 and 
124, respectively; for EGFR and HER-2/neu — clones 
3B5 and E30, respectively; for E-cadherin, α- and 
β-catenin and VEGF — clones NCH-38, α-catenin-1, 
β-catenin-1 and VG1, respectively. All specific 
monoclonal antibodies belong to Dako Cytomation 
(Denmark). The visualization of immunohistochemi-
cal reaction was provided using Envision+ kit and 
3,3-diaminobenzidin (Dako Cytomation, Denmark) 
and hematoxylin staining. The results of immunohis-
tochemical staining were interpreted as follows: tumors 
were considered as positive if the number of cells with 
nuclear staining for p53 was greater than 5% and if the 
number of cells with cytoplasmic reaction for other 
studied proteins was more then 20% [16].
Statistical analysis. All data were expressed 
as a mean ± SE. Differences between groups were 
examined for statistical significance using Student’s 
t-test. p < 0.05 denoted the presence of a statistically 
significant difference.
It was found that application of AV has resulted 
in the increase of 3-year overall survival of patients 
having stage III of disease by more than 30%, but those 
having stage IV — only around 14% (Table 2).
Table 2. 3-year overall survival of GC patients according to TNM stage
TNM stage 3-year overall survival (%) pGroup A Group B
ІІІ 70.8 ± 5.6 39.4 ± 8.5 < 0.05
IV 40.9 ± 10.5 26.7 ± 11.4
The increase of 3-year overall survival of patients 
with metastases in lymph nodes (N1–2) was observed 
also in more than 30% (Table 3).
Table 3. 3-year overall survival of GC patients according to pN stage
pN stage 3-year overall survival (%) pGroup A Group B
N0 81.2 ± 4.7 67.7 ± 8.4
N1–2 54.3 ± 6,5 23.1 ± 6.7 < 0.05
The 3-year survival rate of patients with well-diffe-
rentiated tumors has been increased almost by 22%; 
and with poorly-differentiated — by 27% after AV ap-
plication (Table 4).
Table 4. 3-year overall survival of GC patients according to grade 
of differentiation
Grade of differen-
tiation (G)
3-year overall survival, % pGroup A Group B
G1–2 77.4 ± 7.5 55.6 ± 11.7
G3–4 67.6 ± 4.5 40.4 ± 6.8 < 0.05
Moreover it was also observed the increase 
of 3-year survival rate among patients with tumors 
of Т3 and Т4 categories and who have been treated 
with AV by 22% and 42%, respectively.
Very important data were obtained after the analy-
sis of 5-year overall survival of patients of groups A 
and B (Table 5). It is seen that every year more pa-
tients with GC are alive when they were treated with 
AV after surgical operation. But to provide statistical 
analysis as to the 5-year overall survival of patients 
with GC it needs further observations.
Table 5. 5-year overall survival of GC patients
Groups 1 year 2 year 3 year 4 year 5 year
Group A 86.6 ± 3.1* 75.5 ± 5.1* 71.4 ± 3.7* 64.6 ± 4.8* 51.6 ± 5.2
Group B 69.4 ± 6.2 52.2 ± 7.1 43.5 ± 6.3 40.1 ± 5.7 34.8 ± 5.1
*p < 0.05 compared with group B.
Analysis of the immunohistochemical investigation 
has shown, that patients with the Т3 and Т4 categories 
who have been treated with AV have more favo rable 
prognosis (Table 6). Particularly, they had more 
higher α-catenin expression and lower expressions 
of р53 and VEGF in tumor tissue.
Table 6. Expression of molecular markers in gastric tumor and 
pT category (in %)
Marker T3 T4Group A Group B Group A Group B
EGFR 26.47 ± 5.12 58.33 ± 8.45 14.50 ± 2.11 48.25 ± 7.74
VEGF 35.29 ± 5.38 26.13 ± 5.02 36.00 ± 3.25 50.00 ± 8.04
p53 72.35 ± 7.45 65.00 ± 8.68 62.90 ± 5.06 75.33 ± 10.12
Bcl-2 18.82 ± 3.12 25.25 ± 4.98 22.25 ± 2.48 25.00 ± 6.45
α-catenin 38.24 ± 5.50 24.66 ± 4.85 37.50 ± 3.38 23.33 ± 6.23
β-catenin 55.88 ± 6.33 33.33 ± 6.50 33.50 ± 3.02 26.00 ± 6.77
E-cadherin 47.06 ± 5.94 41.67 ± 6.89 55.50 ± 5.02 52.16 ± 9.89
HER2/neu 29.41 ± 5.22 35.33 ± 6.77 34.33 ± 3.31 25.00 ± 6.45
It was revealed the tendency for decrease of EGFR 
expression (decline to 19.0%), and increase both 
of Bcl-2 expression (up to 40 %) and VEGF (up to 69%) 
in tumor tissue of patients with diffuse type of GC.
It has been found that important features of tumor 
tissue of patients without metastases into lymph nodes 
are the absence of HER-2/neu, р53 and VEGF and the 
presence of Е-cadherin and α-catenin expressions.
None the less it has been observed a significant 
increase of 3-year survival (by 31%) even among 
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patients with unfavorable prognosis (more higher 
р53 expression and more lower level of α-catenin) 
in group A with metastases into lymph nodes.
It was also shown that expression of studied factors 
have not been depended on tumor differentiation but 
we confirmed that well-differentiated gastric tumors 
may be characterized by the presence of E-cadherin, 
β-catenin, EGFR and HER-2/neu and also by the ab-
sence of VEGF, that is agree with literature data and 
is considered as the favorable prognosis.
Survival of such patients is one of the main criteria 
of cancer treatment efficiency. We have tried to estab-
lish the association between expression of the studied 
proteins and GC patients’ survival rates. Particularly, 
we have shown that cells of tumor of patients with 
GC who lived less than a year were characterized by the 
presence of EGFR, Her-2/neu, VEGF, p53, Bcl-2, and 
by the absence of E-cadherin and α-catenin expres-
sions.
It has been shown significant differences in 
overall survival of patients treated with AV (group A) 
and operation only (group B) (Table 6). It may prove 
that AV application in the treatment of patients with 
unfavorable immunophenotype (presence of mutant 
р53, β-catenin, tyrosine kinase receptors EGFR and 
HER-2neu) increases the chance to live more than 
one year compared to patients, who have been treated 
with operation only.
It has been suggested the optimal phenotype for 
vaccine application: р53(+), EGFR(+), HER-2neu (+), 
β-catenin (+), VEGF(+) and Bcl-2(+) with no depen-
dence on E-cadherin and α-catenin presence.
We have seen that immunohistochemical evalua-
tion of Е-cadherin, α-catenin, VEGF, р53, Bcl-2 and 
Her2/neu is the most informative. It has been shown 
that AV application in the treatment of patients having 
stages III or IV significantly increased. But the best 
effect of AV application was observed in patients with 
GC in category Т3–4 with metastases in lymph nodes 
(N1–2), without distant metastases (М0) and in poorly-
differentiated tumors.
It is worth to note that our previous studies con-
cerning the efficiency of AV application in the treatment 
of patients with colorectal [17] and lung [18] cancers 
have shown that it is also more preferably to use 
AV to treat the patients having stage ІІІ of the disease 
with metastases in lymph nodes.
Above presented data permitted to suggest that 
evaluation of the expression of molecular markers 
should be done before the application of AV in the 
treatment of patients with GC to predict unfavorable 
prognosis.
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